RHPS has just mentioned the above in an e-mail, they have gone up 240% today - started at 0.60 and finished up at 1.65. Look to be quite interesting.

@Howard0181 yes there certainly was a lot of movement around that time.

Shareprice has been very quiet, needs another RNS to liven it up I think..

Good luck Howard!

Rns out tomorrow, expecting good things for SAR!

Can't wait. Are you still around Tabasco? If so hope you are well.

Research Update.

Half Yearly Report.

Financial highlights

The Company has traded in line with the Board's expectations

Loss on ordinary activities (after taxation) of £327,000 (2010: Loss of £258,000)

Cash at bank at period end was £530,000 (2010: £621,000)

Operational highlights

Programme research and commercialisation making good progress

Pre-clinical development candidate nominated in Chk1 programme

Chk1 programme presented at major international cancer conferences

3m your post 192
if price rallies from here he will probly still be around .if not, he probly wont.at least not in that guise.
good luck to you.
regards
jkd

Good luck to you to jkd whomever you are.

Well, well then, up 0.95 on todays news - it was flying before the news came out so how come everyone knows before we do as to what is happening??? A vicious circle. However looks like if they get a partner it may do well.

Clear as mud :- Drug Discovery – Cancer & Auto-Immune Disease Drug Programmes

It has taken a long time to find a partner, they started looking in March last year, they are either very picky or what they have is not too tempting. Perhaps they are simply asking for too much in return. Time will tell, let's hope it is a short time not another 17 months!

SAR having a good day today, recouped y'days' profit takers. only need it to reach 2.14p to break even!!

Just over 3p for me I am afraid, at least it is on the move.

some life here.

3M could you put a chart in the header.....please.,.

cracking today

A small chart as a temporary measure whilst 3m is away on her hols soaking up the sunshine!

Final Results

Operational Highlights

Significant progress on its drug research programmes including:

nomination of a pre-clinical development candidate from its Chk1 programme
positive in vivo results from its TYK2 programme

Presentations of research data at high profile international scientific and business conferences

Financial Highlights

£252,500 (before expenses) raised through two share placings

Cash at bank and in hand of £511,000 (2011: £871,000)

Loss on ordinary activities (after taxation) £651,000 (2011: £568,000 loss) in line with
expectations and reflecting planned increase in R&D spend

Since the year-end, agreement on a £4m SEDA financing facility from Yorkville Associates (announced 10 September 2012)

Thanks kim for putting up the chart - I still haven't mastered how to do it.

Everything quiet on the Western Front.